45 results about "Cytomegalovirus infection" patented technology

The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.

A novel means by which HCMV infection can be detected with a high sensitivity and whose practicality is high is disclosed. The present inventors synthesized as many as 15 kinds of HCMV proteins in their full length forms, and intensively studied their reactivities with sera from HCMV-infected patients to find that all the infected patients can be detected without fail when using the pp28 full length protein as an antigen. The pp28 full length protein can be synthesized and purified as a recombinant protein in a large scale by using Escherichia coli, and can be commercially used as an antigen for HCMV tests.

The invention relates to ganciclovir powder-injection for injection, and particularly relates to a medicine composition. The ganciclovir powder-injection comprises ganciclovir, sodium hydroxide, sodium chloride and an optional acidifying or alkalizing agent. The medicine composition serving as an excellent antivirus drug can be used for preventing and treating life or vision-threatening immunodeficiency patients infected with cytomegalovirus and cytomegalovirus infection-related organ grafting patients. The medicine composition has excellent pharmacy property.

The invention discloses a method for establishing a mouse lung cytomegalovirus latent reactivation infection model. The method comprises the following steps: injecting MCMV into the abdominal cavity of a mouse to establish mouse lung latent infection cytomegalovirus, selecting latent MCMV-infected mouse, orally taking a medicine prednisone to induce reactivation of the lung latent cytomegalovirus,and identifying reactivation of the lung latent cytomegalovirus. Lung latent cytomegalovirus infection is induced to be reactivated by orally taking the medicine prednisone, the mouse lung is subjected to cytomegalovirus latent reactivation infection, and an animal model with cytomegalovirus latent reactivation can be constructed. The mouse model shows the typical characteristic of lung cytomegalovirus latent reactivation that: a virus expression-related protein appears in lung tissues. The model can be used for fundamental research in the related fields of cytomegalovirus infection, and laysan experimental animal foundation for exploring the pathogenesis of latent reactivation of cytomegalovirus.

The invention discloses a human cytomegalo virus immunogen fusion protein which comprises flagellin, human cytomegalo virus envelope glycoprotein or polypeptide segment; the invention discloses deoxyribonucleic acid (DNA) molecules used for encoding the fusion protein, recombinant plasmid containing the DNA molecules, and a recombinant expression vector; the invention discloses a preparation method and usage of the fusion protein; and the invention also discloses a human cytomegalo virus vaccine. The fusion protein is high in immunogenicity and can be used for stimulating an organism to generate a great deal of cytomegalo virus antibodies and preparing the vaccine for preventing diseases caused by cytomegalo virus infection and is good in clinical application prospect.

The invention relates to a hybridoma cell strain and a monoclonal antibody secreted by the hybridoma cell strain. The antibody can be specifically bound with human IgM, and can be used for in-vitro detection of the human IgM, and especially suitable for the early diagnosis of cytomegalovirus infection. The invention further relates to a kit containing the hybridoma cell strains or the monoclonal antibodies.

The present invention provides methods and compositions for treating and / or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus IL-10 protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.

The invention provides a cDNA sequence of siRNA aiming at a cytomegalovirus UL86 gene of human, and the nucleotide sequence is: 5`-GCACGTCAGTTATCATCAACA-3`. According to the design principle of the siRNA, the cDNA sequence of the selected siRNA has a GC content of 42.9 percent, and the selected siRNA is corresponding to 3161-3181 nucleotide sites in UL86 mRNA, siRNA eukaryotic expression vectors aiming at the HCMV UL86 gene are constructed, and plasmids are extracted after transforming Escherichia coli for transfecting AD293 cells, thereby effectively inhibiting the UL86 gene mRNA and the protein expression level, and the sequence can be applied to the preparation of drugs for curing cytomegalovirus infection of human.

A Xiduofuwei injection in the form of freeze-dried powder for treating AIDS, cytomegalovirus infection of retina, hepes, simplex virus infection, variola virus infection, etc is prepared from Xiduofuwei, and excipient through proportional dissolving, regulating pH value, filter, quickly freezing, heatingand sublimation drying.

The invention relates to a method for detecting harm degree of postoperative cytomegalovirus infection of a kidney transplantation patient. The invention includes the following steps: a, collecting blood; b, acquiring and analyzing CD19+B lymphocytes; c, preparing cytomegalovirus seeds and quantifying; d, culturing the CD19+B lymphocytes in vitro, and using HCMV to directly and indirectly stimulate the CD19+B lymphocytes; e, performing flow detection on expression of a BAFF receptor on the CD19+B lymphocytes; f, detecting apoptosis rate of the CD19+B lymphocytes; g, detecting IgG secretion capability of the CD19+B lymphocytes. By the method, reaction, to HCMV stimulation, of the B lymphocytes of the patient can be analyzed. The method has important value in evaluating chronic rejection which is indirect effect caused by HCMV infection of the kidney transplantation patient.

The invention relates to a kit for detecting human cytomegalovirus nucleic acid. The kit is characterized in that a virus-specific nucleic acid sequence is amplified by adopting a pair of primers; thehuman cytomegalovirus nucleic acid is detected by two fluorescent probes; the human cytomegalovirus nucleic acid in whole-blood, plasma, urea and milk samples can be qualitatively or quantitatively detected at high sensitivity. The kit has the advantages of simplicity, convenience and quickness in operation, and sensitive and accurate detection results, and can be used as an effective auxiliary detection means for human cytomegalovirus infection.

The invention relates to a vidarabine monophosphate pharmaceutical composition and a preparation method thereof. A low dose of the vidarabine monophosphate pharmaceutical composition is effective in treating herpesvirus infection or cytomegalovirus infection in children 0 to 14 years old, and the toxic and side effect and the increase in medical cost caused by a high-dose or ultrahigh-dose administering manner of 5-10 mg / kg reported in documents are avoided.

Disclosed is a family of corroles for its use in the treatment of an infection by human herpesvirus, especially in the treatment of an infection by human cytomegalovirus.

The invention discloses new application of a ginseng extract, ginsenoside and a ginsenoside derivative in the preparation of a medicine for treating HCMV infection related diseases. The related diseases comprise HCMV infection caused in the process of treating cardiovascular and cerebrovascular diseases, organ transplantation, perinatal periods, tumors, burn, AIDS and other diseases of patients. Tests prove that the ginseng extract, the ginsenoside and the ginsenoside derivative have a remarkable curative effect, quick response and a small toxic or side effect during treatment of HCMV infected diseases, are a medicine or a health product for treating the HCMV infection, which is safe, efficient and stable and has a simple preparation process, and are suitable for industrial production and easy to popularize. In the invention, a new medicine source is provided for the treatment of the HCMV infection.

The invention discloses small nucleic acid for inhibiting human cytomegalovirus infection as well as a preparation and application thereof. The small nucleic acid for inhibiting human cytomegalovirusinfection has nucleotide sequences as shown in SEQ ID NO.1-3. According to the invention, the small nucleic acid is mainly used as a therapeutic drug to prevent further expression of related proteinsof HCMV-related genes, and meanwhile, targeting molecules capable of being combined with the small nucleic acid are designed for surface characteristics of virus-infected cells to improve the phagocytic efficiency of an action site of the small nucleic acid, so that the treatment concentration of the lesion action site is improved, the treatment effect is enhanced, meanwhile the uptake rate of thenon-target tissue is reduced to reduce the potential toxicity, and an effective solution is provided for HCMV infection in-vivo treatment.

According to the application of the NK cells, the NK cell reinfusion preparation and the combined preparation, NK cell reinfusion can prevent cytomegalovirus infection, eliminate cytomegalovirus infection and promote immune reestablishment of the NK cells, the NK cell reinfusion is safe and good in tolerance, serious side effects related to infusion do not occur, and in addition, the NK cell reinfusion preparation can be used for preventing cytomegalovirus infection, eliminating cytomegalovirus infection and promoting immune reestablishment of the NK cells. By adopting the NK cell reinfusion, the occurrence of virus drug-resistant strains is not caused, a series of drug side effects such as obvious myelosuppression and renal function impairment are also not caused, and the phenotype of the reconstructed NK cell in the body of a patient after the NK cell reinfusion is more mature and the function is stronger.

The invention discloses a human cytomegalovirus immunogen fusion protein, which includes flagellin, and human cytomegalovirus envelope glycoprotein or its polypeptide fragment; the invention discloses a DNA molecule encoding the aforementioned fusion protein, and a DNA molecule comprising the DNA Molecular recombinant plasmid and recombinant expression vector; the invention discloses the preparation method and application of the fusion protein; the invention also discloses a human cytomegalovirus vaccine. The fusion protein of the invention has strong immunogenicity, can stimulate the body to produce a large amount of anti-cytomegalovirus antibodies, is used for preparing vaccines to prevent diseases caused by cytomegalovirus infection, and has good clinical application prospects.

The present invention provides methods and compositions for treating and / or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus interleukin-10 (IL-10) protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.

The invention discloses a scourge-clearing toxin-vanquishing traditional Chinese medicine composition for animals and its preparation method. The scourge-clearing toxin-vanquishing traditional Chinesemedicine composition for animals is prepared from, by weight, 10 parts of ephedra, 20 parts of honeysuckle 15 parts of Gardenia jasminoides, 15 parts of Codonopsis pilosula, 15 parts of radix rehmanniae, 15 parts of semen cuscutae, 10 parts of Scutellaria baicalensis, 10 parts of cortex moutan, 25 parts of gypsum, 15 parts of liquorice, 20 parts of lophatherum gracile, 16 parts of radix scrophulariae, 25 parts of fructus forsythia, 30 parts of rhizoma anemarrhenae, 20 parts of radix paeoniae rubrathe, 10 parts of Platycodon grandiflorum, 15 parts of isatis root, 2 parts of lotus plumule, 10 parts of radix angelicae, 10 parts of radix bupleuri, and 10 parts of almond. The preparation includes steps of material preparation; first immersion; secondary immersion; drug taking; stirring; package in bottle. Through analyzing cytomegalovirus infection by the view of traditional chinese medicine, the cytomegalovirus infection belongs to the liver-fire and internal depression, wind toxin infection, deficiency of spleen and kidney yin, phlegm toxic heat hysteresis; the traditional Chinese medicines for clearing heat and detoxifying, removing heat from the liver and activating blood, warmingand supplementing liver deficiency, relieving rheumatic pains and reducing phlegm are combined as the treatment drug and prepared to be injection drug; thus the shortcoming of difficultly feeding andeating traditional Chinese medicine is overcame, the effect is rapidly played, and the treatment effect is significant.

The invention relates to ganciclovir powder-injection for injection, and particularly relates to a medicine composition. The ganciclovir powder-injection comprises ganciclovir, sodium hydroxide, sodium chloride and an optional acidifying or alkalizing agent. The medicine composition serving as an excellent antivirus drug can be used for preventing and treating life or vision-threatening immunodeficiency patients infected with cytomegalovirus and cytomegalovirus infection-related organ grafting patients. The medicine composition has excellent pharmacy property.

The invention provides a diagnostic reagent for human cytomegalovirus infection. The diagnostic reagent comprises human cytomegalovirus DNA PCR amplification primers, a miRNA-UL112-3p forward PCR amplification primer, and a miRNA-UL112-5p forward PCR amplification primer. The diagnostic reagent adopts a PCR method, and is used for detecting the miR-UL112 level of a peripheral blood mononuclear cell of non-tumorous patients (comprising 57 patients with positive HCMV-specific CD8<+>T lymphocytes and 35 patients with negative HCMV-specific CD8<+>T lymphocytes) and tumor patients treated with chemotherapy; the detection results are that levels of miR-UL-112-3p and 5p among groups are significantly different; and the detection results show that the levels of the miR-UL-112-3p and the 5p have certain diagnostic value for HCMV latency and excitation of infection.